[Breaking] GL Pharmtech Receives IND Approval for Phase 3 Trial of Oral Drug W2505… Up to 228 Subjects at 16 Korean Institutions
GL Pharmtech announced that it has received approval from the Ministry of Food and Drug Safety (MFDS) for its Phase 3 investigational new drug (IND) application for the oral drug W2505. The approval date is August 20, 2026, and the clinical trial is being conducted to develop an improved domestic tr
![[Breaking] GL Pharmtech Receives IND Approval for Phase 3 Trial of Oral Drug W2505… Up to 228 Subjects at 16 Korean Institutions](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579783%2F4e4da2bfb8f012b9%2Foriginal.webp&w=1920&q=75)
GL Pharmtech announced that it has received approval from the Ministry of Food and Drug Safety (MFDS) for its Phase 3 investigational new drug (IND) application for the oral drug W2505. The approval date is August 20, 2026, and the clinical trial is being conducted to develop an improved domestic treatment for urological conditions.
The trial design is a prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of W2505.
Up to 228 Subjects at 16 Korean Medical Institutions… Completion Expected in August 2028
The clinical trial will be conducted at 16 medical institutions in South Korea with up to 228 subjects. The trial period is within 24 months of the approval date, with an expected completion date of August 19, 2028.
The primary endpoint is the change in IIEF-EF domain score at 12 weeks after administration of the investigational product compared to baseline. For statistical testing, the primary efficacy endpoint will be tested at a significance level of 2.5% using a one-sided test, while the remaining tests, including exploratory endpoints, will be conducted at a significance level of 5% using two-sided tests.
The company noted that the study design, number of subjects, and trial sites may change depending on the future progress of the clinical trial. The expected completion date is also based on the schedule in the clinical trial protocol application and may be changed later.
Application Filed by GL Pharma… Disclosed Under GL Pharmtech Name After Merger Completion
The clinical trial was applied for by GL Pharma on June 15, 2026, but was disclosed under the name of GL Pharmtech after the merger registration between the two companies was completed on August 4 of the same year, followed by the trial's approval.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Samsung Heavy Industries Wins 342.4 Billion Won Order for One LNG Carrier... 3.2% of Last Year's Revenue](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F579439%2F403aa2853abfc80b%2Fvariants%2Fhero.webp&w=1920&q=75)
